Scottish HTA Body OKs Vyxeos & Prevymis, But Rejects Kymriah In Lymphoma

 
• By Ian Schofield
  
Benefit_Cost
The SMC has weighed the evidence for three rare disease therapies • Source: Shutterstock

More from Health Technology Assessment

More from Market Access